Renascience Inc. (TYO:4889)

Renascience Income Statement

Financials in millions JPY. Fiscal year is April - March.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Revenue	132	194	100	139	209
Revenue Growth (YoY)	-31.96%	94.00%	-28.06%	-33.49%	190.28%
Cost of Revenue	4	29	-	59	29
Gross Profit	128	165	100	80	180
Selling, General & Admin	159	167	185	193	265
Research & Development	132	236	235	82	-
Other Operating Expenses	16	13	13	13	-
Operating Expenses	307	417	434	291	265
Operating Income	-179	-252	-334	-211	-85
Interest Expense	-	-	-	-5	-7
Currency Exchange Gain (Loss)	-1	-	-	-	1
Other Non Operating Income (Expenses)	1	-1	-	-26	-
EBT Excluding Unusual Items	-179	-253	-334	-242	-91
Asset Writedown	-1	-4	-	-11	-
Other Unusual Items	323	-	-	-	-9
Pretax Income	143	-257	-334	-253	-100
Income Tax Expense	30	1	1	1	-
Net Income	113	-258	-335	-254	-100
Net Income to Common	113	-258	-335	-254	-100
Shares Outstanding (Basic)	13	13	13	11	10
Shares Outstanding (Diluted)	13	13	13	11	10
Shares Change (YoY)	-	-	11.61%	15.99%	0.00%
EPS (Basic)	8.89	-20.30	-26.35	-22.30	-10.18
EPS (Diluted)	8.89	-20.30	-26.35	-22.30	-10.18
Free Cash Flow	-176	-231	-286	-231	-
Free Cash Flow Per Share	-13.85	-18.17	-22.50	-20.28	-
Gross Margin	96.97%	85.05%	100.00%	57.55%	86.12%
Operating Margin	-135.61%	-129.90%	-334.00%	-151.80%	-40.67%
Profit Margin	85.61%	-132.99%	-335.00%	-182.73%	-47.85%
Free Cash Flow Margin	-133.33%	-119.07%	-286.00%	-166.19%	-
EBITDA	-178	-251	-333	-208	-
EBITDA Margin	-134.85%	-129.38%	-	-149.64%	-
D&A For EBITDA	1	1	1	3	-
EBIT	-179	-252	-334	-211	-85
EBIT Margin	-135.61%	-129.90%	-	-151.80%	-40.67%
Effective Tax Rate	20.98%	-	-	-	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.